Influenza vaccinations for at-risk groups and their immediate family starting at HUS: COVID-19 vaccines also available to at-risk groups in Meilahti Tower Hospital
Influenza and COVID-19 vaccines are given in Meilahti Tower Hospital from September 30, 2024. Hyvinkää Hospital and New Children's Hospital will begin vaccinating against influenza and COVID-19 in October.
Vaccines are given in Meilahti Tower Hospital every weekday for the first two weeks. From October 14, vaccinations are on Mondays, Wednesdays, and Fridays. The vaccination point in Meilahti Tower Hospital is open until November 6.
The first few days may be busy so be prepared to wait. Alternatively, you can visit at a later date.
While waiting to be vaccinated, we recommend that you wear a face mask, which is given to everyone at the vaccination point upon arrival. You cannot come in for vaccination if you have symptoms of a respiratory infection.
Read more about at-risk groups on the website of the Finnish Institute for Health and Welfare
The influenza vaccine is available at the Meilahti Tower Hospital, Hyvinkää Hospital and New Children's Hospital without appointment to people at risk of severe influenza who live in Uusimaa and their immediate family members. More on who's at-risk on the THL (Finnish National Institute for Health and Welfare) website (in Finnish)
The COVID-19 vaccine is available at Meilahti Tower Hospital and Hyvinkää Hospital without appointment to people at risk of severe COVID-19 who live in Uusimaa. More on who's at-risk on the THL (Finnish National Institute for Health and Welfare) website (in Finnish)
You can check the vaccination points at HUS hospitals and their opening hours on our website at hus.fi.
Keywords
Contacts
Eeva RuotsalainenDeputy Chief Physician, Epidemiological Unit
Tel:050 427 9117eeva.ruotsalainen@hus.fiAbout HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
En ny sjukdom som orsakar kortväxthet har upptäckts24.9.2024 15:37:29 EEST | Pressmeddelande
Forskare vid HUS och Helsingfors universitet har deltagit i en amerikansk studie där man identifierade en ny genetisk defekt som orsakar tillväxtstörningar och en helt ny genetisk sjukdom.
Uusi lyhytkasvuisuutta aiheuttava sairaus löytyi24.9.2024 15:37:29 EEST | Tiedote
HUSin ja Helsingin yliopiston tutkijat olivat mukana yhdysvaltalaistutkimuksessa, jossa tunnistetiin uusi kasvuhäiriötä aiheuttava geenivirhe ja kokonaan uusi geneettinen sairaus.
Ändringen av förordningen som gäller utökad vaccinationsrätt omsätts i praktiken – farmaceuter hjälper till med vaccinationer på hälsostationerna i Helsingfors stad24.9.2024 09:51:34 EEST | Pressmeddelande
På hälsostationerna i Helsingfors stad har man i höst inlett ett försök, där HUS Apoteks farmaceuter deltar i corona- och influensavaccinationer som vaccinatörer.
Rokotusoikeuden laajenemista koskeva asetusmuutos käytäntöön – farmaseutit helpottamaan rokotuksia Helsingin kaupungin terveysasemilla24.9.2024 09:51:34 EEST | Tiedote
Helsingin kaupungin terveysasemilla on tänä syksynä alkanut kokeilu, jossa HUS Apteekin farmaseutteja on mukana korona- ja influenssarokotuksissa rokottajina.
Förebyggande av RS-virusinfektioner hos småbarn är under uppstart17.9.2024 09:07:30 EEST | Pressmeddelande
I Finland kommer man i oktober–november att börja ge en ny slags antikropp, det vill säga nirsevimab som utvecklats mot RS-virus, till spädbarn under tre månader och barn under ett år som hör till en riskgrupp för allvarlig RS-virusinfektion. Målet med den är att förebygga största delen av fallen med allvarlig sjukdom hos och sjukhusvård av spädbarn till följd av RS-virus.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom